On September 24, 2024, Asahi Kasei Pharma entered into a final agreement with Nagase & Co., Ltd. (Nagase) to transfer its diagnostics business, including the Ohito Pharmaceuticals Plant and Ohito Office (the “Transfer”), to Nagase.
1. Purpose of the Transfer
Asahi Kasei Group is focused on growing its Health Care sector, particularly in medical devices, pharmaceuticals, and bioprocessing. To prioritize investment in these areas, a strategic review led to the decision to transfer the diagnostics business to Nagase, a company well-positioned to drive growth through its strong presence and technological capabilities in bio-related fields.
2. Scope of the Transfer
The transfer encompasses:
- All activities related to the manufacturing, development, and sales of diagnostic reagents and enzymes.
- The Ohito Pharmaceuticals Plant, which produces raw materials for diagnostic enzymes and active ingredients for pharmaceuticals like Bredinin™.
- The Ohito Office, responsible for infrastructure management in the Ohito District.
- 3.Overview of Nagase
- Established in 1832, Nagase has built expertise across multiple industries, with a focus on chemicals and biotechnology. The company aims to use the acquired assets to advance its vision of creating a sustainable world, leveraging its extensive R&D network and biotechnological capabilities.
4. Transfer Configuration
Effective July 1, 2025, Asahi Kasei Pharma will transfer its rights, obligations, and facilities in the Ohito District to a newly established subsidiary, which will then be acquired by Nagase. Key departments excluded from the transfer, such as the Pharmaceuticals Research Center, will remain under Asahi Kasei Pharma.
5. Future Outlook
Post-transfer, the Ohito Pharmaceuticals Plant will continue to supply active pharmaceutical ingredients to Asahi Kasei Pharma through an outsourcing agreement, ensuring a stable supply chain.
